Publications by authors named "E Imyanitov"
Diversity of the Circulating Tumor Markers: Perspectives of a Multimodal Liquid Biopsy.
Biochemistry (Mosc)
November 2024
Article Synopsis
- Liquid biopsy has become an essential tool over the last decade for diagnosing and managing various malignant tumors, offering benefits like early detection and monitoring of treatment response.
- This method typically analyzes tumor-derived components from blood, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and others, but often fails to detect these markers in a significant number of patients.
- The review highlights the potential of a multiparametric approach that tests multiple biomarkers simultaneously, which could enhance sensitivity and provide a more accurate understanding of cancer progression and treatment outcomes.
Use of 3' Rapid Amplification of cDNA Ends (3' RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas.
Int J Mol Sci
November 2024
Targeted treatment of advanced or metastatic urothelial carcinomas (UCs) requires the identification of druggable mutations. This study describes the development of a 3' Rapid Amplification of cDNA Ends (3' RACE)-based targeted RNA sequencing panel which accounts for the status of all genes relevant to UC treatment, namely, , , , , (), () and . -activating point mutations or fusions were found in 54/233 (23.
View Article and Find Full Text PDFArticle Synopsis
- - Prolgolimab is an improved anti-PD-1 antibody that shows strong efficacy in treating metastatic melanoma and features a modified LALA mutation.
- - Comparative studies indicate that prolgolimab has higher PD-1 receptor occupancy and T-cell activation than conventional antibodies like nivolumab and pembrolizumab, while showing less activation of antibody-dependent cellular phagocytosis.
- - In mouse studies, prolgolimab inhibited tumor growth by 56%, significantly outperforming pembrolizumab's 16% inhibition, suggesting a need for clinical comparisons between IgG1 and IgG4 anti-PD-1 antibodies.
Purpose: Female carriers of germline BRCA1 mutations almost invariably develop breast cancer (BC); however, the age at onset is a subject of variation. We hypothesized that the age-related penetrance of BRCA1 mutations may depend on inherited variability in the host immune system.
Methods: Next-generation sequencing was utilized for genotyping of HLA class I/II genes (HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQB1, and HLA-DRB1/3/4/5) in patients with BRCA1-associated BC with early (< / = 38 years, n = 215) and late (> / = 58 years, n = 108) age at onset.